Crystal Structure Analysis of La2Ni6CoD(x) During Deuterium Absorption Process.

The crystal structures of La2Ni6CoD(x) (x = 5.2 and 9.6) were determined by in situ neutron diffraction along the P-C isotherm.

Crystal structure and cyclic hydrogenation property of Pr4MgNi19.

The hydrogen absorption-desorption property and the crystal structure of Pr4MgNi19 was investigated by pressure-composition isotherm measurement and X-ray diffraction (XRD). Pr4MgNi19 consisted of two phases: 52.9% Ce5Co19-type structure (3R) and 47.

Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.

It is known that the lipid-lowering agent pravastatin, which is not metabolized by cytochrome P450, is eliminated as an unchanged drug in bile and urine. It is interesting to note that the non-renal clearance of pravastatin in end-stage renal failure patients is decreased compared with that of healthy volunteers. This study investigated the influence of uremic serum and toxins on the transport mechanisms of pravastatin to elucidate the cause of decreased non-renal clearance in end-stage renal failure patients.

Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.

Objectives: The purpose of this study was to clarify the cause of decreased metabolic clearance of losartan in patients with end-stage renal failure. The influence of serum from haemodialysis patients (uraemic serum) and uraemic toxins on the metabolism of losartan to EXP-3174 was investigated in vitro.

Methods: The formation of EXP-3174 was estimated using pooled human liver microsomes.